GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4SC AG (FRA:VSC) » Definitions » Cash And Cash Equivalents

4SC AG (FRA:VSC) Cash And Cash Equivalents : €4.43 Mil (As of Jun. 2024)


View and export this data going back to 2005. Start your Free Trial

What is 4SC AG Cash And Cash Equivalents?

4SC AG's quarterly cash and cash equivalents declined from Jun. 2023 (€12.16 Mil) to Dec. 2023 (€8.32 Mil) but then stayed the same from Dec. 2023 (€8.32 Mil) to Jun. 2024 (€4.43 Mil).

4SC AG's annual cash and cash equivalents declined from Dec. 2021 (€24.10 Mil) to Dec. 2022 (€14.82 Mil) and declined from Dec. 2022 (€14.82 Mil) to Dec. 2023 (€8.32 Mil).


4SC AG Cash And Cash Equivalents Historical Data

The historical data trend for 4SC AG's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4SC AG Cash And Cash Equivalents Chart

4SC AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 31.73 24.20 24.10 14.82 8.32

4SC AG Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.85 14.82 12.16 8.32 4.43

4SC AG Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


4SC AG  (FRA:VSC) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


4SC AG Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of 4SC AG's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


4SC AG Business Description

Industry
Traded in Other Exchanges
Address
Fraunhoferstrasse 22, Planegg-Martinsried, DEU, 82152
4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. Its pipeline is protected by a comprehensive portfolio of patents and currently comprises two drug candidates in clinical development resminostat and Domatinostat. The geographic area of the company is Germany, the EU, and Other countries, and the majority of the revenue comes from Other Countries.

4SC AG Headlines

No Headlines